Akari Therapeutics, Plc (AKTX)
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
$38.13M
Dr. David Solomon
9.00
New York City, NEW YORK
Jan 31, 2014
-1.05
$-2.99
0.48
0.58
0.00%
-1.55
-0.03
-8.44
0.00
0.58
-396.64%
1,043.99%
Similar stocks (10)
Soleno Therapeutics, Inc.
SLNO
Capricor Therapeutics, Inc.
CAPR
Armata Pharmaceuticals, Inc.
ARMP
Anebulo Pharmaceuticals, Inc.
ANEB
Pulmatrix, Inc.
PULM
Sonnet BioTherapeutics Holdings, Inc.
SONN
Processa Pharmaceuticals, Inc.
PCSA
Salarius Pharmaceuticals, Inc.
SLRX
Histogen Inc.
HSTO
Scopus BioPharma Inc.
SCPS
Similar stocks (10)
Soleno Therapeutics, Inc.
SLNO
Capricor Therapeutics, Inc.
CAPR
Armata Pharmaceuticals, Inc.
ARMP
Anebulo Pharmaceuticals, Inc.
ANEB
Pulmatrix, Inc.
PULM
Sonnet BioTherapeutics Holdings, Inc.
SONN
Processa Pharmaceuticals, Inc.
PCSA
Salarius Pharmaceuticals, Inc.
SLRX
Histogen Inc.
HSTO
Scopus BioPharma Inc.
SCPS